You are here: Home: Audio Program Guide: BCU Think Tank 1 | 2007 Audio: BCU Think Tank 1 | 2007
 

 
  Go to Section 1
Go to Section 2
Go to Section 3
Go to Section 4
Go to Section 5
Go to Section 6

 

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.


Section 1:

Adjuvant Endocrine Therapy
   Click here to download the entire section  
Track 1 Delayed adjuvant therapy with aromatase inhibitors
Track 2 Defining a time limit for the benefit of delayed adjuvant endocrine interventions
Track 3 Compliance with oral endocrine therapy
Track 4 Natural history of node-negative and node-positive, hormone receptor-positive disease
Track 5 Extended adjuvant therapy with aromatase inhibitors beyond five years
Track 6 Long-term estrogen deprivation and neuropsychiatric function

Track 7 Clinical approach to patients who have received five years of an adjuvant aromatase inhibitor
Track 8 HER2 as a marker of relative resistance to endocrine therapy
Track 9 Selection of initial endocrine therapy in postmenopausal patients
Track 10 Up-front use of adjuvant aromatase inhibitors versus sequencing after tamoxifen

Section 2:

HER2-Positive Disease
   Click here to download the entire section  
Track 1 First-line therapy for patients with hormone receptor-positive, HER2-positive visceral metastases: Implications of the TAnDEM data
Track 2 Clinical implications of the TAnDEM data for women with asymptomatic metastatic disease
Track 3 Durable responses to a combination of trastuzumab and an aromatase inhibitor in the palliative setting
Track 4 Incorporation of TCH and bevacizumab into the next generation of adjuvant trials for HER2-positive disease: Proposed NSABP/BCIRG adjuvant trial
Track 5 Adjuvant chemotherapeutic options to combine with trastuzumab
Track 6 Shifting treatment patterns in HER2-positive, early breast cancer

Track 7 Risk-benefit issues in the selection of adjuvant TCH for HER2-positive, early breast cancer
Track 8 Perspective on advances in the treatment of HER2-positive, early breast cancer
Track 9 Use of adjuvant trastuzumab for patients with smaller node-negative tumors
Audio
Track 10 Use of adjuvant trastuzumab monotherapy
Audio
Track 11 Optimal duration of adjuvant trastuzumab
Audio
Track 12 Reduced risk of cardiac toxicity with TCH
Audio
Track 13 Emerging adjuvant clinical trial strategies in HER2-positive disease
Audio
Track 14 The ALTTO trial: Trastuzumab, lapatinib, the sequence or combination with chemotherapy
Audio
Track 15 Cardiac safety issues in combining trastuzumab and bevacizumab in the adjuvant setting
Audio
Track 16 Clinical equipoise in ALTTO and the proposed NSABP/BCIRG adjuvant trial in HER2-positive disease
Audio
Track 17 Safety issues in trials of adjuvant bevacizumab
Audio
Track 18 Evaluation of cMYC as a prognostic factor in early breast cancer
Audio
Track 19 Evaluation of host and tumor factors in clinical trials
Audio
Track 20 Dose-dense AC arrowpaclitaxel with trastuzumab for HER2-positive, early breast cancer
Audio

Section 3:

Adjuvant Chemotherapy
   Click here to download the entire section  
Track 1 Dose-dense AC arrowpaclitaxel with trastuzumab for HER2-positive, early breast cancer (continued)
Track 2 Benefits of adjuvant chemotherapy for patients with hormone receptor-positive disease
Track 3 Selection of adjuvant chemotherapy for patients with node-positive breast cancer
Track 4 Adjuvant dose-dense AC without a taxane
Track 5 Antitumor efficacy of dose-dense AC
Track 6 Taxane scheduling in adjuvant chemotherapy

Track 7 Clinical use of dose-dense ACarrowpaclitaxel/ trastuzumab
Track 8 Correlative tissue studies to identify molecular predictors of response to therapies
Track 9 Long-term implications of trastuzumab-associated cardiotoxicity
Track 10 A devolving role for adjuvant chemotherapy in select patient subsets
Track 11 US Oncology trial of adjuvant docetaxel/cyclophosphamide (TC) versus AC
Track 12 Tolerability and side effects of adjuvant TC
Track 13 Adjuvant TC for patients with lower-risk, early breast cancer
Track 14 Capecitabine as a potential alternative to CMF in the adjuvant setting
Arrow
Track 15 Implications of ECOG-E2197 comparing adjuvant doxorubicin/docetaxel to AC chemotherapy
Arrow
Track 16 Concerns about long-term anthracycline-associated cardiotoxicity
Arrow
Track 17 TAILORx: Hormone therapy with or without chemotherapy for patients with intermediate recurrence scores on Oncotype DX™
Arrow
Track 18 Defining intermediate recurrence scores in TAILORx
Arrow
Track 19 Use of standard prognostic factors to estimate recurrence risk
Arrow
Track 20 Poor reliability and precision in standard clinical assays
Arrow
Track 21 Advantages of the Oncotype DX assay’s precision and ability to identify predictive factors
Arrow
Track 22 Use of the Oncotype DX multigene assay in clinical practice
Arrow

Section 4:

Systemic Therapy of Metastatic Disease
   Click here to download the entire section  
Track 1 Clinical implications of ECOG-E2100 and treatment with bevacizumab beyond the first-line setting
Track 2 Flexibility in expanding the scope of bevacizumab beyond use with paclitaxel in the first-line setting
Track 3 Side effects and tolerability of bevacizumab
Track 4 Long-term responders to capecitabine/bevacizumab in the metastatic setting
Track 5 Value of bevacizumab for patients with asymptomatic metastatic disease in the absence of a survival advantage
Arrow
Track 6 Expected benefit from the incorporation of bevacizumab into the adjuvant setting
Arrow
Track 7 Advantage of shorter infusion time and lack of premedication with nanoparticle albumin-bound (nab) paclitaxel
Arrow
Track 8 Need for head-to-head clinical trials comparing nab paclitaxel with standard taxane dose and schedules
Arrow
Track 9 Evaluation of nab paclitaxel in the adjuvant setting
Arrow
Track 10 NSABP Phase II trial of neoadjuvant chemotherapy with sequential weekly nab paclitaxel followed by FEC
Arrow

Section 5:

Endocrine Therapy of Metastatic Disease
   Click here to download the entire section  
Track 1 EFECT: Equivalence of fulvestrant and exemestane as second-line or later therapy
Track 2 Patient preferences for oral versus parenteral therapy
Track 3 Clinical trial strategies evaluating fulvestrant in combination with the aromatase inhibitors

Section 6:

Lifestyle Modifications
   Click here to download the entire section  
Track 1 Clinical implications of dietary fat reduction and breast cancer recurrence in WINS
Track 2 Increased interest in clinical trial initiatives evaluating lifestyle interventions
Track 3 Evaluation of biologic effects of dietary alterations in the preoperative setting
Track 4 Deficiency of physical activity among breast cancer patients and survivors
Track 5 Dietary fat recommendations for breast cancer patients